Intercell vaccine gets U.S. pediatric approval
VIENNA (Reuters) - Austria's Intercell said on Tuesday it has won U.S. regulatory approval for pediatric use of its Ixiaro vaccine to protect against Japanese Encephalitis (JE), a step it had achieved in Europe in February.
"For the first time in nearly two years, a licensed vaccine will now be available to vaccinate traveling children and children of forward-deployed military personal in Asia as well against JE," Chief Executive Thomas Lingelbach said in a statement, calling the step a key growth element for the product.
(Reporting by Michael Shields; Editing by David Cowell)
- Target says data from 40 million cards stolen in holiday period
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Special Report: Why Ukraine spurned the EU and embraced Russia
- Facebook, Zuckerberg, banks must face IPO lawsuit: judge
- U.S. prosecutor defends treatment of Indian diplomat |